Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,704,475
  • Shares Outstanding, K 56,965
  • Annual Sales, $ 9,200 K
  • Annual Income, $ -453,810 K
  • 60-Month Beta 0.66
  • Price/Sales 610.63
  • Price/Cash Flow N/A
  • Price/Book 8.86
Trade ASND with:

Options Overview Details

View History
  • Implied Volatility 70.39% ( -0.76%)
  • Historical Volatility 53.39%
  • IV Percentile 72%
  • IV Rank 37.44%
  • IV High 122.98% on 02/24/22
  • IV Low 38.91% on 10/20/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 22
  • Volume Avg (30-Day) 1,114
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 25,429
  • Open Int (30-Day) 9,924

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -2.50
  • Number of Estimates 7
  • High Estimate -2.22
  • Low Estimate -2.67
  • Prior Year -1.73
  • Growth Rate Est. (year over year) -44.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
85.67 +16.89%
on 08/31/22
109.98 -8.95%
on 09/15/22
+9.83 (+10.88%)
since 08/26/22
3-Month
82.70 +21.09%
on 07/15/22
110.39 -9.29%
on 08/12/22
+5.04 (+5.30%)
since 06/27/22
52-Week
61.58 +62.62%
on 05/12/22
172.65 -42.00%
on 10/12/21
-63.27 (-38.72%)
since 09/27/21

Most Recent Stories

More News
Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results

—  U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission...

ASND : 100.14 (+1.51%)
Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10

COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call...

ASND : 100.14 (+1.51%)
Can Elevance Health (ELV) Beat Q2 Earnings on Membership Growth?

Elevance Health's (ELV) second-quarter results are likely to reflect improved Commercial Business operations, driven by the robust growth in risk-based areas.

CNC : 77.30 (-0.53%)
ASND : 100.14 (+1.51%)
AFMD : 1.9800 (+1.02%)
ELV : 445.98 (-0.48%)
Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

All matters approved by shareholdersTwo new directors elected to the board TORONTO, June 30, 2022 (GLOBE NEWSWIRE) -- Ascendant Resources Inc....

ASDRF : 0.1100 (-8.33%)
ASND.TO : 0.1450 (-3.33%)
ASND : 100.14 (+1.51%)
Why Ascendis Pharma Stock Is Sinking Today

Investors are reacting negatively to the company's Q1 update.

ASND : 100.14 (+1.51%)
Ascendis Pharma A/S Reports First Quarter 2022 Financial Results

Phase 3 PaTHway Trial top-line results demonstrated potential of TransCon™ PTH to become the first parathyroid replacement therapy for adults with...

ASND : 100.14 (+1.51%)
Why Ascendis Pharma (ASND) Might Surprise This Earnings Season

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ASND : 100.14 (+1.51%)
Why Encompass Health (EHC) is Down 2.4% Since Q1 Earnings Beat

Encompass Health Corporation (EHC) looks to unveil eight additional de novo locations this year and increase its bed count.

ANGN : 0.9216 (+1.27%)
ASND : 100.14 (+1.51%)
EHC : 46.13 (-1.77%)
LABP : 0.6368 (-2.97%)
Vermilion Energy (VET) to Report Q1 Earnings: What's in Store?

A favorable commodity pricing scenario is likely to have aided Vermilion Energy's (VET) earnings in Q1.

ADI : 141.81 (+0.70%)
AAP : 159.31 (+1.03%)
VET : 20.32 (+10.37%)
ASND : 100.14 (+1.51%)
Teladoc (TDOC) Plunges 40.3% Since Q1 Earnings Beat: Here's Why

Teladoc Health's (TDOC) bet on mental health service BetterHelp is likely to generate lower yield this year.

ANGN : 0.9216 (+1.27%)
TDOC : 26.63 (+0.79%)
ASND : 100.14 (+1.51%)
APTX : 0.3910 (-2.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

3rd Resistance Point 106.03
2nd Resistance Point 103.67
1st Resistance Point 101.90
Last Price 100.14
1st Support Level 97.77
2nd Support Level 95.41
3rd Support Level 93.64

See More

52-Week High 172.65
Fibonacci 61.8% 130.22
Fibonacci 50% 117.11
Fibonacci 38.2% 104.01
Last Price 100.14
52-Week Low 61.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar